A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS
一项针对急性髓系白血病 (AML) 或骨髓增生异常综合征 (MDS) 患者的 I 期、首次人体剂量递增研究，旨在评估 JNJ-74856665（二氢乳清酸脱氢酶抑制剂）单药或联合用药的疗效。
期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.20224
Searle, Emma; Cluzeau, Thomas; O'Nions, Jenny; Recher, Christian; Gyan, Emmanuel; Morillo, Daniel; Esteve, Jordi; Kulasekararaj, Austin; Raffoux, Emmanuel; Walter, Harriet S; Pigneux, Arnaud; Valcárcel, David; Daskalakis, Nikki; Bussolari, Jacqueline; Pietsch, E Christine; Kuduk, Scott; Bush, Tammy; Zhang, Xiaochun; Philippar, Ulrike; Oluwasanjo, Adetokunbo; Bradford, Kathryn; Miller, Jonathan; Van Bogaert, Charlotte; Curtis, Martin; Chang, Shih-Yu; Guttke, Christina; Gaj, Stan; Pearson, Rachel; Murphy, Joseph; van Dijck, Wim; Alfonso Piérola, Ana
